Dopamine (DA) is a major neurotransmitter important for neuroendocrine control and recent studies have described genomic signaling pathways activated and inhibited by DA agonists and antagonists in the goldfish brain. Here we perform a meta-type analysis using microarray datasets from experiments conducted with female goldfish to characterize the gene expression responses that underlie dopaminergic signaling. Sexually mature, pre-spawning [gonadosomatic index (GSI) = 4.5 ± 1.3%] or sexually regressing (GSI = 3 ± 0.4%) female goldfish (15-40 g) injected intraperitoneally with either SKF 38393, LY 171555, SCH 23390, sulpiride, or a combination of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and α-methyl-ptyrosine. Microarray meta-type analysis identified 268 genes in the telencephalon and hypothalamus as having reciprocal (i.e., opposite between agonism and antagonism/depletion) fold change responses, suggesting that these transcripts are likely targets for DA-mediated regulation. Noteworthy genes included ependymin, vimentin, and aromatase, genes that support the significance of DA in neuronal plasticity and tissue remodeling. Sub-network enrichment analysis (SNEA) was used to identify common gene regulators and binding proteins associated with the differentially expressed genes mediated by DA. SNEA analysis identified gene expression targets that were related to three major categories that included cell signaling (STAT3, SP1, SMAD, Jun/Fos), immune response (IL-6, IL-1β, TNFs, cytokine, NF-κB), and cell proliferation and growth (IGF1, TGFβ1). These gene networks are also known to be associated with neurodegenerative disorders such as Parkinsons' disease, well-known to be associated with loss of dopaminergic neurons. This study identifies genes and networks that underlie DA signaling in the vertebrate CNS and provides targets that may be key neuroendocrine regulators. The results provide a foundation for future work on dopaminergic regulation of gene expression in fish model systems.
INTRODUCTION
Dopamine (DA) is a neurotransmitter important in disorders such as schizophrenia (Seeman and Kapur, 2000) and Parkinson's disease (Baik et al., 1995) , but is also the major neurotransmitter controlling teleost reproduction (reviewed in Dufour et al., 2005; Dufour et al., 2010) . In this regard, DA inhibits the release of luteinizing hormone (LH) in fish through multiple mechanisms: (a) DA inhibits gonadotropin-releasing hormone (GnRH) release from GnRH neurons through the D1 receptor (Yu and Peter, 1992) ; (b) DA directly inhibits LH release from gonadotrophs in the anterior pituitary through the D2 receptor (Peter et al., 1986; Omeljaniuk et al., 1987) ; (c) DA decreases the expression of GnRH receptor mRNA in the pituitary (Kumakura et al., 2003; Levavi-Sivan et al., 2004) ; and (d) DA inhibits the synthesis of GABA (Hibbert et al., 2004 (Hibbert et al., , 2005 , an important stimulator of LH release (Martyniuk et al., 2007) . Furthermore, it is well understood that DA, acting through the D1, stimulates growth hormone in fish (Wong et al., 1992) . Our recent studies using goldfish have investigated the effects of DA agonists on the hypothalamic transcriptome and proteome (Popesku et al., 2010) or of DA antagonists on gene expression in the neuroendocrine brain (Popesku et al., 2011a) . Additionally, we have previously described the effects of a combination of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP; a selective DA neurotoxin) and α-methyl-p-tyrosine (αMPT; a tyrosine hydroxylase inhibitor) on the goldfish hypothalamic transcriptome . Using microarray datasets from two of these experiments, and an additional novel microarray data presented here, we further elucidate the mechanistic effects of DA on gene expression in the neuroendocrine brain by performing a meta-type analysis of these datasets.
In transcriptomics, there are a number of bioinformatics approaches to globally assess gene expression data and to organize expression data into a larger biological context. These methods include Gene Ontology (GO) characterization, functional enrichment, and pathway analysis. Many of these approaches have been successfully performed using genomic data in neuroendocrine regions of teleost fishes to better describe cellular events that are mediated by neurotransmitters, hormones, or exogenous neuroactive agents (Marlatt et al., 2008; Popesku et al., 2008; Zhang et al., 2009a; Martyniuk et al., 2010) . New bioinformatics tools are now www.frontiersin.org available to construct gene networks using gene expression profiling and have been used successfully in teleost fish (e.g., reverse engineering of adverse pathways for ecotoxicology (Perkins et al., 2011) . Sub-network enrichment analysis (SNEA; Ariadne's Pathway Studio v7.0 Sivachenko et al., 2007) offers a unique approach to protein interaction networks that are described in the literature as well as a curated mammalian database. Specifically, SNEA builds sub-networks by mapping experimental data onto known bio-molecular interactions. The interactions include promoterbinding, protein modification, and common targets of expression. This algorithm has been used to identify gene sub-networks in breast cancer cell lines (Chuang et al., 2007) and is a useful tool for identifying interaction or signaling networks that involve differentially expressed genes. As such, this method can provide insight in gene regulatory pathways.
In this study, we identify genes and sub-networks that are likely regulated by DA based on their reciprocal response to DA agonism or antagonism/depletion. These data have implications for our understanding of DA action in fish neuroendocrine systems.
MATERIALS AND METHODS
This is a meta-type analysis of published experiments involving treatments of goldfish with DA agonists (Popesku et al., 2010) , antagonists (Popesku et al., 2011a) , and after pharmacological depletion of DA . The abbreviated Materials and Methods pertaining to the experiments are included here for completeness. It should be noted that, while published, the previous DA depletion studies offered only a cursory analysis of the microarray data in the context of neurotransmitter effects on gene expression and did not specifically address global dopaminergic control of transcriptional responses. Furthermore, we present novel transcriptomic data for specific DA antagonism for which the physiological response to these antagonists has been published (Popesku et al., 2011a) , but for which microarray analysis was not performed at that time. We used this novel dataset to compare these DA antagonism responses to agonist and DA depletion responses to improve identification of DA-regulated transcripts in the hypothalamus.
EXPERIMENTAL ANIMALS AND CONDITIONS
All procedures used were approved by the University of Ottawa Protocol Review Committee and followed standard Canadian Council on Animal Care guidelines on the use of animals in research.
Common adult female goldfish were purchased from a commercial supplier (Aleong's International Inc., Mississauga, ON, Canada) and maintained at 18˚C under a natural simulated photoperiod on standard flaked goldfish food. Fish were allowed to acclimate for a minimum of 1 month prior to any experimental manipulations. Goldfish were anesthetized using 3-aminobenzoic acid ethylester (MS222) for all handling, injection, and dissection procedures.
DOPAMINE AGONIST EXPERIMENT
Sexually mature, pre-spawning [mid-May; gonadosomatic index (GSI) = 4.5 ± 1.3%] female goldfish (15-40 g) were injected intraperitoneally with either SKF 38393 [D1 agonist; SKF; 3, 4, or LY 171555 [D2 agonist; LY; (−)-Quinpirole hydrochloride] purchased from Tocris (Ballwin, MO, USA). The experimental design and doses chosen were based on Otto et al. (1999) who showed rapid effects on goldfish brain somatostatin mRNAs. LY was dissolved in physiological saline (0.6% NaCl) to yield a dose of 2 µg/g body weight of fish. SKF was first dissolved in a minimal amount of dimethylsulfoxide (DMSO), and subsequently diluted to 40 µg/g body weight of fish with physiological saline (0.6% for fish). The final concentration of DMSO was 0.099%; DMSO up to 0.1% does not affect basal GH or LH levels (Otto et al., 1999) . While 0.1% DMSO may (Mortensen and Arukwe, 2006) or may not (Nishimura et al., 2008) affect gene expression, all of our gene expression work is relative to control fish which received an equivalent amount of DMSO. The fish received two sequential i.p. injections at 5 µL/g body weight each according to the schedule shown in Table 1 . The experiment was conducted this way to ensure that all fish received an equivalent volume of vehicle.
DOPAMINE ANTAGONIST EXPERIMENT
The DA D1-specific antagonist SCH 23390 and DA D2-specific antagonist sulpiride were purchased from Tocris (Ballwin, MO, USA). The antagonists were first dissolved in a minimal amount of DMSO, and subsequently diluted with 0.6% saline. The final concentration of DMSO was 0.099%. Sexually regressing (June; GSI = 3 ± 0.4%; n = 18 each) female goldfish received a single injection at 5 µL/g body weight of either SCH 23390 or sulpiride to give a dose of 40 µg/g or 2 µg/g body weight of fish, respectively, or saline containing an equivalent amount of DMSO.
DOPAMINE DEPLETION EXPERIMENT
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine and α-methyl-ptyrosine (αMPT) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Sexually mature (May; GSI = 4.7 ± 0.6%) female goldfish (n = 5 each) were injected with MPTP (50 µg/g; day 0) and αMPT (240 µg/g; day 5) or saline (control) in order to severely deplete catecholamines. Our previous work had established effective doses of MPTP and αMPT in goldfish (Trudeau et al., 1993; Hibbert et al., 2004) .
TISSUE DISSECTIONS
Fish were sacrificed by spinal transection and hypothalami and telencephali tissues were rapidly dissected and immediately frozen on dry ice. Brain tissues were pooled (2-3 hypothalami or telencephali/tube) to increase RNA yield prior to RNA isolation. For the agonists and antagonists, tissues were harvested 5 h post-injection, and for the DA depletion experiment, tissues were harvested 20 h after the αMPT injection. The cerebellae of the fish from the DA depletion experiment were also harvested for brain catecholamine levels, but were not used in further analyses.
RNA ISOLATION, QUANTIFICATION, AND QUALITY ASSESSMENT
RNA was isolated with the TRIzol method (Invitrogen, Burlington, ON, Canada) per the manufacturer's protocol. Samples were treated with DNase on-column in an RNeasy Mini Plus kit (Qiagen, Mississauga, ON, Canada). RNA quantity was evaluated using the NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific). RNA integrity was evaluated using the BioAnalyzer (Agilent); RIN for each sample was >8.4.
HPLC ANALYSIS OF BRAIN CATECHOLAMINE LEVELS IN THE DOPAMINE DEPLETION EXPERIMENT
Catecholamine levels in brain tissues were determined on aluminaextracted samples (100 µL) using HPLC with electrochemical detection (Woodward, 1982) . The HPLC incorporated a Varian ProStar 410 solvent delivery system (Varian Chromatography Systems, Walnut Creek, CA, USA) coupled to a Princeton Applied Research 400 electrochemical detector (EG & G Instruments, Princeton, NJ, USA). Concentrations were calculated relative to appropriate standards, using 3,4-dihydroxybenzalamine hydrobromide (DHBA) as an internal standard.
MICROARRAY HYBRIDIZATIONS
For all microarray analyses, cDNA was synthesized from 2 µg total RNA according to the Genisphere 3DNA Array 900MPX kit according to the manufacturer's protocol (Genisphere, Hatfield, PA, USA). We previously described and validated the production and use of our goldfish-carp cDNA microarray (Martyniuk et al., 2006; Marlatt et al., 2008; Mennigen et al., 2008) , and a detailed description of the microarray is available (Williams et al., 2008) . Four microarray hybridizations were performed for each hypothalamic and telencephalic tissue pool for both D1 and D2 agonists (total of 16 arrays), antagonists (16 arrays), or DA depletion (MPTP + αMPT; eight arrays) to screen for the effects of the DA in the neuroendocrine brain. For each experiment, three separate pools of RNA from treated fish were hybridized to the microarrays, and a fourth hybridization was a replicate dye-reversal of one of the three RNA pooled samples. Hybridizations were carried out relative to a common pool of control samples (∼30 control fish) for each tissue, which decreases technical variation as only one reference is utilized while maintaining biological variation of the treatment samples (Churchill, 2002) . All cDNA synthesis, labeling, and hybridizations were performed using the Genisphere 3DNA Array 900MPX kit according to the manufacturer's protocol (Genisphere, Hatfield, PA, USA). Hybridizations and scanning protocols were described previously (Martyniuk et al., 2006; Marlatt et al., 2008; Mennigen et al., 2008) . Briefly, microarrays were scanned at full-speed 10-µm resolution with the ScanArray 5000 XL system (Packard Biosciences/PerkinElmer, Woodbridge, ON, Canada) using both red and blue lasers. Images were obtained with ScanArray Express software using automatic calibration sensitivity varying photomultiplier (PMT) gain (PMT starting at 65% for Cy5 and 70% for Cy3) with fixed laser power at 80% and the target intensity set for 90%. Microarray images were analyzed with QuantArray (Packard Biosciences/Perkin Elmer), and raw signal intensity values were obtained for duplicate spots of genes. Raw intensity values for all microarray data and microarray platform information have been deposited in the NCBI Gene Expression Omnibus database and assigned the following SuperSeries accession numbers: GSE15855 (agonists), GSE15763 (antagonists), and GSE16044 (MPTP + αMPT). Generalized Procrustes Analysis was used for normalization of the array data and the Significance Analysis of Microarrays (SAM) method (Woodward, 1982; Tusher et al., 2001 ) was used to identify differentially expressed genes. Genes/ESTs were selected based on identical AURATUS GeneIDs and on the basis of differential regulation in opposite directions for MPTP or the antagonists vs. agonists, or in the same direction for MPTP vs. antagonists; genes that did not fall into one of these categories were not included in the analysis. All genes/ESTs identified and presented were statistically significant (q < 5%) in all treatments.
REAL-TIME PCR
Primers used in this study for aromatase B, 18S, and β-actin have been validated and published (Martyniuk et al., 2006 
SUB-NETWORK ENRICHMENT ANALYSIS OF RECIPROCALLY DA-REGULATED TRANSCRIPTS
Pathway Studio 7.1 (Ariadne, Rockville, MD, USA) and ResNet 7.0 were used for SNEA for genes that showed reciprocal expression with MPTP-mediated DA depletion and with the DA agonist SKF 38393. We selected the agonist and DA depletion datasets from the hypothalamus for this analysis because (1) the experiments were conducted at the same time of year (May) and (2) these experiments resulted in the greatest number of reciprocal gene expression changes. A total of 114 genes were successfully mapped to human homologs using the GenBank protein ID while 14 genes www.frontiersin.org
could not be confidently mapped to human homologs; hence the unmapped proteins were not included in the analysis. SNEA for expression targets, binding partners, and post-translation modification targets was performed to determine if there were common gene targets for MPTP and SKF treatments. SNEA creates a central "seed" from all relevant entities in the database, to find common effectors (expression targets, binding partners, and posttranslational targets). The enrichment p-value for gene seeds was set at p < 0.05 and, for the current study, the criteria of greater than five members per group were required for inclusion as a significantly regulated gene network. This was chosen to focus the analysis and discussion on the most likely gene networks regulated through DA signaling.
RESULTS

CATECHOLAMINE DEPLETION
To ensure that the MPTP + αMPT treatment effectively decreased DA levels in the brain, Hyp, Tel, and cerebellum (Cer) tissues were analyzed for catecholamine content using HPLC. Following injections of MPTP (−6 days) and αMPT (−1 day), DA levels were decreased by 69.6 and 70.9% in the Hyp and Tel, respectively, and by 88.2% in the Cer relative to saline-injected controls (Figure 1) . Norepinephrine (NE) levels were also reduced in the Hyp (79.4%), Tel (87.5%), and Cer (90.4%).
MICROARRAY ANALYSIS
Using the microarray datasets from our previous experiments (Popesku et al., , 2010 , and the novel microarray data from the antagonist experiment, a meta-type analysis of genes likely regulated by DA was performed. A total of 268 genes/ESTs were identified in the hypothalamus as being regulated by DA, while only four were identified in the telencephalon. Of the 268 genes/ESTs identified in the hypothalamus, only 41% are annotated ( Figure A1 in Appendix). The others currently have no known biological function (6%), are not similar to any sequences in GenBank (34%), or are lacking sequence information (19%). The relatively high number of sequences affected by DA in the hypothalamus, the majority of which are acting through the D1 receptor (Table 2) , highlights the importance of this receptor in this tissue. The annotated sequences were binned into their corresponding GO Slim terms, using Blast2GO as described in Popesku et al., 2010 ; Figure 2 ).
REAL-TIME RT-PCR VALIDATION OF AromB
Changes in the hypothalamic mRNA levels of Aromatase B identified by microarray analysis were validated using real-time RT-PCR. Figure 3 shows a 4.7-fold decrease (p = 0.027) in AromB mRNA levels 5 h post-injection with SKF 38393. AromB mRNA levels were increased 1.6-fold following DA depletion, but did not reach statistical significance (p > 0.05).
SNEA
Sub-network enrichment analysis identified a number gene set targets for MPTP-mediated DA depletion and SKF 38393 ( Table 3) . Expression targets of insulin (INS) were highly affected by DA deletion and receptor stimulation ( Figure 4A ). This expression group included genes such as apoe and apoa4, vim, gapdh, and myc. Expression targets also affected by DA depletion and SKF 38393 were those related to cell signaling, for example expression targets of STAT3, SMAD, JUN, and SP1 signaling. A second major group of expression targets included those related to inflammation such as cytokines, NF-κB, IL-6, IL-1β, and TNF. Genes involved in cytokine signaling that are reciprocally affected by dopaminergic stimulation/inhibition included fn1, cyp19a1, psmd4, vim, and glul ( Figure 4B ). The third group involved expression targets related to cell growth and differentiation such as insulin-like growth factor I (IGF1) and transforming growth factor-beta (TGFβ1; Figure 4C ). Also noteworthy was that expression targets of HIF1A were also identified in the SNEA analysis (Table 3) . SNEA is also able to identify binding partner networks and post-translational targets using differentially expressed genes. Binding partners of vitamin D, GAPDH, myosin, and tubulin were affected by treatments while protein modification targets of trypsin and glutathione transferase were significantly impacted through DA signaling ( Table 3 ).
DISCUSSION
Our approach is an effort to identify a group of genes that are likely regulated by DA. The principle behind the analysis is that genes commonly affected in one direction by severe catecholamine depletion (MPTP + αMPT) and/or DA antagonists will also be affected by DA agonists but expression changes will be in the opposite direction. The power and novelty of this analysis lies in the physiological manipulation and biological validation of reciprocal fold-changes between DA agonists and antagonists/depletion in vivo, rather than the technical validation resulting from different techniques performed on the same samples. Additionally, we validated the expression of brain aromatase in the hypothalamus (discussed below) using real-time RT-PCR.
Here we present transcripts that are affected by wellcharacterized dopaminergic manipulations and allow for speculation on DAergic mechanisms of action in the goldfish neuroendocrine brain. Furthermore, our analysis identified gene networks and provides the foundation for future work on DAergic regulation of neuroendocrine gene expression. Some of the genes/ESTs identified in this analysis (e.g., calmodulin, apolipoprotein) were previously discussed (Popesku et al., 2010) and will not be discussed here. It is not our intention to examine all of the genes/ESTs listed in Table 2 , but we have selected some to discuss in terms of current and emerging ideas in dopaminergic neuron (dys)function. The genes/ESTs below are discussed relative to DA receptor stimulation. The DA agonists and the DA depletion experiments provided the greatest number of reciprocal changes in gene expression compared to the DA antagonist experiment, which is likely due to the fact that both the agonist and depletion experiments were conducted at the same time of year (May) when the fish were of similar sexual maturity (GSI ∼4.6%) compared to the antagonist experiment (June) when fish were sexually regressing (GSI ∼3%). The difference in the number of gene changes between these time points highlights the importance of seasonality of dopaminergic action in the neuroendocrine brain of fish (Zhang et al., 2009b) . Indeed, the inhibitory tone of DA on gonadotropin release at these times of year indicate that the fish are in different physiological states (Trudeau et al., 1993; Vacher et al., 2002) and thus may respond to DAergic manipulation differently. This is apparent in some of the genes listed in Table 2 (full list in Table A1 in Appendix), and is a limitation of our approach. We are, however, comparing the effects of DAergic manipulation against paired control fish and are looking for genes that are consistently differentially expressed as a result of that manipulation. While few genes were differentially expressed in the DA antagonist experiment when compared to the other two datasets, the new microarray data presented here provides some further insight into teleost brain function.
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Norepinephrine levels were severely reduced in addition to DA levels in MPTP + αMPT-treated fish; however, the genes discussed below are limited to those showing opposite changes to specific DA agonists supporting the hypothesis that genes are therefore likely regulated by DA itself.
The identification of ependymin and vimentin in the hypothalamus highlights the significance of neuronal plasticity and tissue remodeling in response to DAergic manipulations. Ependymin is an extracellular glycoprotein and neurotrophic growth factor involved in optic nerve regeneration, synaptic plasticity, and long-term potentiation in Cypriniformes (Shashoua, 1991; Adams and Shashoua, 1994; Adams et al., 1996) . Moreover, ependymin was shown to be overexpressed in regenerating echinoderms (Suarez-Castillo et al., 2004) . Ependymin-related proteins were identified in amphibians and mammals (Suarez-Castillo and Garcia-Arraras, 2007) and Shashoua et al. (2001) showed that a short fragment of goldfish ependymin was able to activate the AP-1 transcription factor in neuroblastoma and primary rat brain cortical cultures. Similarly, vimentin is an intermediate filament and is known to increase during cerebellar regeneration in the brown ghost knifefish, Apteronotus leptorynchus (Clint and Zupanc, 2002) . At least 2 forms of vimentin exist in goldfish (Glasgow et al., 1994) , and while the current analysis is unable to resolve the form(s) of vimentin regulated by DA, it is likely that both of the sequences listed in Table 2 correspond to the same form, as they share nearly identical expression patterns in response to DA. Both vimentin and ependymin, along with α-and β-actin and tubulins (Table 2) were decreased in response to DA, supporting the role of DA in synaptic plasticity and tissue remodeling (Kauer and Malenka, 2007) . Cytoskeletal remodeling is hypothesized to be important for hormone secretion from the anterior pituitary in mammals (Ravindra and Grosvenor, 1990) . Furthermore, Ravindra and Grosvenor (1988) demonstrated that domperidone, a D2-specific antagonist that does not cross the blood-brain barrier but can act on the pituitary, increased prolactin (PRL) levels as well as pituitary polymerized tubulin levels, similar to levels seen in suckling rats. This response, the authors observed, was blocked by bromocriptine, a D2-specific agonist supporting a role www.frontiersin.org were first converted to GO-Slim annotations (goslim_generic.obo) and the multilevel chart was constructed using a sequence convergence cutoff of five (seven for Biological Process) to reduce the complexity of the chart.
for DA in changes observed in the tubulin system in the anterior pituitary. This is relevant because, in fish, it should be noted that DAergic neurons in the mediobasal hypothalamus (e.g., posterior tuberculum) project directly to the pituitary (i.e., are hypophysiotropic; Hornby and Piekut, 1990; Anglade et al., 1993) . This is important as it suggests the need for maintaining DA neuronal populations throughout seasonal reproductive period. The identification of aromatase b (CYP19B, or AroB) in our analysis as being inhibited by DA is of particular interest. Our RT-PCR targeted validation of the decrease in AroB mRNA levels in response to SKF 38393, it also confirmed an opposite change in direction of AroB mRNA levels in response to DA depletion as identified by the microarray. In adult fish, AroB is expressed only in radial glial cells Le Page et al., 2010) , which persist throughout life and serve as neuronal progenitors in the brain.
At least some AroB-immunoreactive (ir) neurons in the medial preoptic area (POA) of the Japanese quail brain respond to DA (Cornil et al., 2004 ) and a few AroB-ir neurons in the POA of the bluehead wrasse are in close proximity with, while a subset appear to co-express, tyrosine hydrolase (TH; Marsh et al., 2006) , the ratelimiting step in DA synthesis and a marker for cathecholaminergic neurons. Moreover, some TH-ir neurons in the POA of rainbow trout express estrogen receptors (Linard et al., 1996) and testosterone and estradiol increase goldfish pituitary DA turnover rates as measured following αMPT-induced catecholamine depletion (Trudeau et al., 1993) . More importantly, DA was shown to reduce aromatase enzyme activity in quail POA homogenates in vitro (Baillien and Balthazart, 1997) . These studies, including the current one, suggest that DA regulates AroB, possibly to modulate the feedback mechanisms of sex steroids on the brain. However, AroB is also important in neurogenesis and brain repair (reviewed in Diotel et al., 2010) . Interestingly, Pollard et al. (1992) showed full recovery of DA levels in the brain of goldfish after 8 days using a moderate dose of MPTP (50 µg/g), and Poli et al. (1992) demonstrated spontaneous recovery of DA and NE levels in the goldfish telencephalon, diencephalon, and medulla after 6 weeks following injection of MPTP at a lower dose (10 µg/g) for three consecutive days. These two studies suggest that in fish, unlike in mammals, DA neurons regenerate following injection with MPTP, and may be linked to higher aromatase activity in the fish brain. This is an avenue of research we are currently conducting.
Multiple genes/ESTs identified as being regulated by DA are involved in the lipid and fatty acid metabolic process or transport. For example, 17β-hydroxysteroid dehydrogenase type 12B (HSD17B12; down), high-density lipoprotein binding protein (HDLBP; up), vitellogenin 2 (vtg2; up), cubulin (CUBN; up), sh3-domain grb-like 2 (SH3GL1; up), StAR-related lipid transfer domain containing 4 (STARD4; down), and sterol-c5-desaturase homolog (SC5DL; up) were identified as being regulated by DA. SC5D is involved in the biosynthesis of cholesterol (Sugawara et al., 2001 ). HSD17B12 reduces 3-ketoacyl-CoA to 3-hydroxyacylCoA in the second step of fatty acid elongation (Moon and Horton, 2003) . In vivo studies in zebrafish demonstrated that HDLBP is not affected by the insulin family or growth hormone, but it is hypothesized that HDLBP is involved in lipid transfer based on its high expression in the liver and ovary (Chen et al., 2003) . CUBN is a high-density lipoprotein receptor (Moestrup and Kozyraki, 2000) and STARD4 is hypothesized to facilitate transport of a cholesterol precursor (Soccio et al., 2002) . Vtg is best characterized as a liver phosphoprotein stimulated by estrogen and then deposited in the ovary (Jalabert, 2005; Kang et al., 2007) , but is, in general, a lipid transport molecule. The changes in these mRNAs suggest lipid mobilization, possibly to derive energy for neuronal remodeling as discussed above.
The granulins are conserved growth factors and are able to stimulate the proliferation of macrophages in goldfish (Hanington et al., 2006) . Granulin also has protease inhibitor activity in invertebrates (Hong and Kang, 1999) and cysteine protease activity in plants (Chen et al., 2006) . Granulin was shown to be relatively lowly expressed in the brain of goldfish (Hanington et al., 2006) and tilapia (Chen et al., 2007 ). It appears as though DA, acting through the D1 receptor, stimulates expression of granulin in the hypothalamus of female goldfish. In the developing rat hypothalamus, it was demonstrated that both estrogen and androgen induced granulin expression (Suzuki et al., 2001 ) and that estrogen induced granulin expression in the dentate gyrus (hippocampus) of adult rats (Chiba et al., 2007) . Furthermore, in hippocampal rat tissue in vitro, estradiol enhanced neural progenitor cell proliferation and this response was blocked by a granulinspecific antibody (Chiba et al., 2007) . Although speculative, this is relevant, as hydroxysteroid (17β) dehydrogenase was identified here as being increased in response to DA, which interconverts 17β-estradiol and estrone, 16-α-hydroxyestrone and estriol, and androstenedione and testosterone Stoffel-Wagner (2003), suggesting that sex steroids influence the DAergic regulation of granulin or, alternatively, the DA modulates estrogen-regulated granulin expression.
Granulin mRNA levels were also identified as being decreased 4.2-fold in the goldfish telencephalon following a 2-days waterborne exposure to 0.1 µM thyroid hormone (T3; Wiens, 2009) . While unconfirmed, this is intriguing because the current study identified transthyretin (TTR) mRNA levels as being significantly increased in response to DA. TTR is a thyroid hormone-binding and transport protein and is necessary for maintaining normal levels of circulating thyroid hormone in plasma (Episkopou et al., 1993) . Furthermore, TTR protein levels are increased in the cerebrospinal fluid (CSF) of rats with degenerating nigrostriatal neurons (Rite et al., 2007) . Future studies aimed at examining the potential interaction between T3 and DA are warranted, particularly as microarray analysis identified increases in mRNA levels of iodothyronine deiodinase type I in the hypothalamus of female fish in response to SKF 38393 and 171555 (D1-and D2-specific agonists, respectively; Popesku et al., 2010) .
The identification of U2 small nuclear RNA auxiliary factor-1 (U2AF1) mRNA levels as being increased by DA acting through the D1 receptor (Table 2) is interesting. There are currently five known small nuclear ribonucleoproteins (snRNPs) that make up the spliceosome (Query, 2009 ). LSM7 protein, whose mRNA levels were also increased in both DA agonist treatments (Popesku et al., 2010 ) also forms part of the spliceosome complex (SalgadoGarrido et al., 1999) . The increase in both of these factors in response to either DA agonist suggests that blockage of either of these receptors would inhibit transcription of particular components of the spliceosome, and thus decrease splicing activity, thereby decreasing the amount of a particular splice variant. The observed decrease of the D2 short isoform splice variant in response to both D1 and D2 antagonists (Popesku et al., 2011b) supports this hypothesis.
www.frontiersin.org Only three annotated genes/ESTs were identified in the telencephalon that were increased in response to D2 receptor agonists and decreased in response to D2 receptor blockage or DA depletion. This indicates that DA, acting through the D2 receptor, regulates these genes/ESTs. That relatively few genes affected by DA manipulation in the telencephalon was a surprising finding. While we expected tissue-specific responses to the various pharmacological treatments, we may have expected more than three genes to be affected in the Tel. In the case of D2 receptor, mRNA levels are high and specifically but widely expressed in regions of both Hyp and Tel of the African cichlid fish, Astatotilapia burtoni (O'Connell et al., 2011) . However, it is not only the expression of receptors that will determine the response to an exogenous pharmacological agent, but also the ongoing effects of endogenous DA levels that are acting on both D1 and D2 receptors in vivo. It is clear in both goldfish and the cichlid, that DAergic innervation in the Hyp and Tel are extensive but clearly different, depending on the specific sub-region of each tissue (Hornby Table 2. and Piekut, 1990; O'Connell et al., 2011) . The clear difference in the global expression patterns in response to the various DA manipulations we report for goldfish Hyp and Tel supports this. Moreover, the type of cells expressing those receptors in each tissue will undoubtedly be different, so we do indeed expect major tissue differences.
Two of the DA-regulated genes/ESTs in the telencephalon are leucine-rich ppr-motif containing protein (LRPPRC) and solute carrier family 2 (facilitated glucose fructose transporter) member 5 (SLC2A5; glucose transporter 5; GLUT5). LRPPRC is a core nucleoid protein (Bogenhagen et al., 2008) and is hypothesized to have a regulatory role in the integration of the cytoskeleton with vesicular trafficking, nucleocytosolic shuttling, transcription, chromosome remodeling, and cytokinesis based on its interactions with other proteins by yeast 2-hybrid analysis (Liu and McKeehan, 2002) . The third gene regulated by D2 in the telencephalon, CCAAT/enhancer-binding protein beta (C/EBPβ), is particularly interesting. CaMKII phosphorylates C/EBPβ (Wegner et al., 1992) , which, in turn, activates transcription factor-1 (ATF1; Shimomura et al., 1996) , among other things. Methamphetamine administration to mice caused a dose-dependent increase in ATF1 and CREB DNA-binding activities . As CaMKIIα protein levels were increased in response to DA agonists (Popesku et al., 2010) , a working hypothesis of DAergic regulation of gene expression in the neuroendocrine brain of goldfish through the increase in ATF1 can thus be put forth.
Sub-network enrichment analysis takes advantage of previously characterized interactions between genes (expression relationships) and proteins (binding relationships). It is also able to associate genes and proteins with cell processes or diseases. The SNEA approach was developed by Ariadne (Pathway Studio®). Briefly, data on molecular interactions are retrieved from www.frontiersin.org the ResNet nine database which is compiled using MedScan. The database contains over 20 million PubMed abstracts and approximately 900 K full-text articles (May 27, 2011) . A background distribution of expression values in the gene list is calculated by an algorithm. This is followed by a statistical comparison between the sub-network and the background distribution using a MannWhitney U -Test, a p-value is generated that indicates the statistical significance of difference between two distributions (additional details can be found in the technical bulletin pg. 717 from Pathway Studio 7.0). SNEA has similar objectives to Ingenuity Pathway analysis and each is a useful tool to visualize molecular datasets. SNEA is different from KEGG which uses well defined biochemical and molecular pathways. SNEA has been applied in biomarker discovery in mammals (Kotelnikova et al., 2012) and for gene and protein networks in teleost fishes Trudeau et al., 2012) . For this study, we chose to use Pathway Studios to visualize our data.
There were three major categories of the SNEA identified in the current study: cell signaling (STAT3, SP1, SMAD, Jun/Fos), immune response (IL-6, IL-1β, and TNF, cytokine, NF-κB), and cell proliferation and growth (IGF1, TGFβ1). Inflammatory pathways modulated by DA have been characterized in mouse models and have been associated with degenerative processes and cytokines released from glial cells play important roles in mediating cellular responses to injury due to neurotoxicants such as MPTP. For example, old male and female transgenic mice injected intraperitoneally with MPTP (15 mg/kg for 2 days at two injections/day) caused males to have dramatic increases in IL-1β luciferase reporter gene activity that correlated to the increased susceptibility of dopaminergic neurons to MPTP toxicity found in old male mice (Bian et al., 2009 ). In the same study, mRNA levels of TNF-α and IL-6 were not changed, but notable here is that genes affected downstream of IL-6 and TNF signaling were altered by DA in the goldfish hypothalamus, suggesting that these signaling cascades can be sensitive to dopaminergic inputs. In support of these data, both mRNA and protein levels for various cytokines and expression of their receptors were significantly increased in the substantia nigra of MPTP-treated mice (Lofrumento et al., 2011) . Here we identify putative gene targets and subsequent genomic effects that may occur after cytokine induction in the vertebrate CNS. A recent review by O'Callaghan et al. (2008) discuss the role of MPTP in inflammation in relation to cytokine signaling, including cytokines identified in the goldfish hypothalamus such as IL-1β and IL-6. Lastly, in regards to the inflammatory response in the goldfish, many of the cell signaling cascades are also involved in the immune response. For example, JAK/STAT3 signaling plays a role in inflammation in the mammalian brain in response to MPTP (Sriram et al., 2004) . Therefore, the gene set node for cell signaling molecules (e.g., STAT) identified in the goldfish may directly stimulate inductions in cytokines.
Gene targets of IGF1 and TGFβ were also affected in expression after DA depletion and DA agonism. IGF1 activates RAS, P13K, and AKT signaling pathway to stimulate growth and differentiation of cells. TGF-β is a member of the transforming growth factor family that is involved in cell differentiation and regulation of the immune system. Both these signaling pathways are known to have a role in dopaminergic signaling and to be associated with the onset of neurodegenerative diseases. There are reports to suggest that IGF signaling may be involved in neuroprotection within the CNS. IGF1 has been shown to have protective role in MPP + induced neurotoxicity in human neuroblastoma SH-EP1 cells by inhibiting apoptotic processes (Wang et al., 2010) and female rats treated with the neurotoxin 6-hydroxydopamine (6-OHDA) did not show reduced tyrosine hydroxylase immunoreactivity (a marker for DA toxicity) after intracerebroventricular infusion of IGF1 substantia nigra compared to those without the treatment (Quesada et al., 2008) . The effect of IGF1 was dependent upon the PI3K/Akt pathway. It is plausible that gene expression changes in the goldfish hypothalamus in response to DA depletion and DA receptor activation are protective responses to DA-mediated neurotoxicity. Tong et al. (2009) investigated IGF distribution in human post-mortem brain tissues and report that IGF-I expression was significantly elevated in the frontal cortex of Parkinson's patients while IGF-II expression was significantly reduced in the frontal white matter of PD patients. Thus, there are complex interactions between different IGF signaling pathways in the neurodegenerative brain (IGF1 and IGF2), however experimental evidence associates IGF in these processes. Similar to IGF1, TGFβ signaling targets are implemented in DA signaling in the goldfish hypothalamus. This pathway has also been implicated in neurodegeneration (Andrews et al., 2006) and the TGFβ signaling pathway can be modulated with DA treatments (Recouvreux et al., 2011) .
Fish models are increasingly being used for investigations into the mechanisms of disease occurrence and progression (Weinreb and Youdim, 2007) . Here we provide examples and demonstrate the usefulness of implementing SNEA to gain increased insight into key regulators underlying neurotransmitter signaling in the neuroendocrine brain and uncover novel associations between disease states and pharmacological treatments. In so doing, we provide a foundation for future work on dopaminergic regulation of gene expression in fish.
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